Four-part CME Webinar Series
Register for each session below to gain access to all webinars.
Focus on Age-related Macular Degeneration
Wednesday , October 12 | 7:00 pm
Focus on Diabetic Retinopathy
Thursday, October 13 | 8:00 pm
Focus on Diabetic Macular Edema
Wednesday, October 19 | 7:00 pm
Focus on Retinal Vein Occlusion
Wednesday, October 26 | 8:00 pm
Real World Retina: Challenges in the Management of Retinal Disease – Focus on Age-related Macular Degeneration
Wednesday, October 12, 2022
7:00 – 9:00 pm ET
Topics
- Trending in 2022: Hot Topics in AMD
- Interpreting the Latest Real-World Data on AMD Treatment
- Real-World Cases in AMD
- Optimizing AMD Treatment
- LIVE Question & Answer
Register Now!
Real World Retina: Challenges in the Management of Retinal Disease – Focus on Diabetic Retinopathy
Thursday, October 13, 2022
8:00 – 10:00 pm ET
Topics
- Trending in 2022: Hot Topics in DR
- Interpreting the Latest Real-World Data on DR Treatment
- Real-World Cases in DR
- Optimizing DR Treatment
- LIVE Question & Answer
Register Now!
Real World Retina: Challenges in the Management of Retinal Disease – Focus on Diabetic Macular Edema
Wednesday, October 19, 2022
7:00 – 9:00 pm ET
Topics
- Trending in 2022: Hot Topics in DME
- Interpreting the Latest Real-World Data on DME Treatment
- Real-World Cases in DME
- Optimizing DME Treatment
- LIVE Question & Answer
Register Now!
Real World Retina: Challenges in the Management of Retinal Diseases – Focus on Retinal Vein Occlusion
Wednesday, October 26, 2022
8:00 – 10:00 pm ET
Topics
- Trending in 2022: Hot Topics in RVO
- Interpreting the Latest Real-World Data on RVO Treatment
- Real-World Cases in RVO
- Optimizing RVO Treatment
- LIVE Question & Answer
Register Now!
Series Overview
Real-world outcomes of patients with retinal diseases treated with intravitreal anti-vascular endothelial growth factor (VEGF) therapies are often suboptimal when compared to the results demonstrated in pinnacle clinical studies. The discrepancies in outcomes have in part been attributed to patients receiving fewer than the recommended number of anti-VEGF injections, as well as patients discontinuing therapy due to treatment burden associated with frequent dosing schedules. New imaging techniques that allow for better monitoring of therapy response, along with the refinement of treatment protocols that extend the interval between treatment dosing, have the potential to reduce treatment burden while providing optimal visual outcomes. In this 4-part webinar series, experts in the field will provide guidance on the management of diabetic retinopathy (DR), diabetic macular edema (DME), neovascular age-related macular degeneration (nAMD), and retinal vein occlusion (RVO). Topics covered include utilizing recent advances in imaging to monitor treatment response in patients with retinal diseases, identification of baseline factors that help predict anti-VEGF therapy outcomes, and evaluation of anti-VEGF treatment outcomes in clinical practice. Furthermore, challenging real-world cases will be presented, allowing for incorporation of the content into clinical practice.
Target Audience
The intended audience for this activity is retina specialists, ophthalmologists, and other health care professionals involved in the management of patients with retinal diseases.
Series Learning Objectives
Upon successful completion of these activities, participants should be better able to:
- Evaluate the evidence for anti-VEGF treatment outcomes in AMD in clinical practice.
- Identify prognostic indicators for predicting anti-VEGF therapy outcomes in patients with AMD.
- Assess the applicability of recent advances in imaging for monitoring treatment response in patients with AMD.
- Evaluate the evidence for anti-VEGF treatment outcomes in DR in clinical practice.
- Identify relevant patient baseline factors for predicting anti-VEGF therapy outcomes in patients with DR.
- Assess the applicability of recent advances in imaging for monitoring treatment response in patients with DR.
- Evaluate the evidence for anti-VEGF treatment outcomes in DME in clinical practice.
- Identify relevant patient baseline factors for predicting anti-VEGF therapy outcomes in patients with DME.
- Assess the applicability of recent advances in imaging for monitoring treatment response in patients with DME.
- Evaluate the evidence for anti-VEGF treatment outcomes in RVO in clinical practice.
- Identify relevant patient baseline factors for predicting anti-VEGF therapy outcomes in patients with RVO.
- Assess the applicability of recent advances in imaging for monitoring treatment response in patients with RVO.
Activity Co-Chairs
Arshad M. Khanani, MD, MA, FASRS
Managing Partner
Director of Clinical Research
Director of Fellowship
Sierra Eye Associates
Clinical Associate Professor
University of Nevada
Reno, NV
John W. Kitchens, MD
Vitreoretinal Surgeon
Retina Associates of Kentucky
Lexington, KY
Carl D. Regillo, MD, FACS
Director, Retina Service
Wills Eye Hospital
Professor of Ophthalmology
Thomas Jefferson University
Mid Atlantic Retina
Philadelphia, PA
Rishi P. Singh, MD
President, Cleveland Clinic Martin North and South Hospitals
Stuart, FL
Center for Ophthalmic Bioinformatics, Cole Eye Institute, Cleveland Clinic
Professor of Ophthalmology, Lerner College of Medicine, Case Western Reserve University
Cleveland, OH
Series Faculty
Caroline R. Baumal, MD, FASRS
Professor of Ophthalmology
New England Eye Center
Tufts University School of Medicine
Boston, MA
Diana V. Do, MD
Vice Chair for Clinical Affairs
Professor of Ophthalmology
Byers Eye Institute
Stanford University School of Medicine
Palo Alto, CA
Nancy M. Holekamp, MD
Director, Retina Services
Pepose Vision Institute
St. Louis, MO
Judy E. Kim, MD, FARVO, FASRS
Professor, Ophthalmology and Visual Sciences
Professor, Graduate School of Biomedical Sciences
Director, Teleophthalmology and Research
Medical College of Wisconsin
Milwaukee, WI
Jennifer I. Lim, MD
Professor of Ophthalmology
Marion H. Schenk Chair and Professor of Ophthalmology
Director of the Retina Service
Vice-Chair for Diversity and Inclusion
Department of Ophthalmology
University of Illinois College of Medicine at Chicago
Chicago, IL
Yasha Modi, MD
Associate Professor of Ophthalmology
New York University
New York, NY
Christina Y. Weng, MD, MBA
Professor of Ophthalmology
Fellowship Program Director, Vitreoretinal Diseases & Surgery
Baylor College of Medicine
Houston, TX
These continuing education activities are provided by
These activities are supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.
For more session-specific information, please visit the registration sites.
Vindico Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will be mitigated prior to the commencement of the activity.
Faculty, topics, program schedule, and credit hours are subject to change. Recording of any manner is prohibited without written permission from Vindico Medical Education, Office of Medical Affairs and Compliance.
Copyright © 2023 Vindico Medical Education | Privacy Policy
856.994.9400 | 6900 Grove Road, Building 100 | Thorofare, New Jersey 08086
A Wyanoke Group Company